KNOWLEDGE TRANSLATION TO IMPROVE PRESCRIPTION OF EVIDENCE-BASED MEDICAL THERAPY FOR PATIENTS ADMITTED WITH ACUTE CORONARY SYNDROMES: INSIGHTS FROM THE AMI-OPTIMA STUDY  by Huynh, Thao et al.
A5
JACC March 17, 2015
Volume 65, Issue 10S
Acute Coronary Syndromes
knowledge tRanslation to impRove pRescRiption oF evidence-based medical 
theRapy FoR patients admitted with acute coRonaRy syndRomes: insights FRom the 
ami-optima study
Moderated Poster Contributions
Acute Coronary Syndromes Moderated Poster Theater, Poster Hall B1
Saturday, March 14, 2015, 11:00 a.m.-11:10 a.m.
Session Title: The Complex Landscape of Acute Coronary Syndromes
Abstract Category: 2. Acute Coronary Syndromes: Clinical
Presentation Number: 1125M-11
Authors: Thao Huynh, Simon Kouz, Marc Afilalo, Stephane Rinfret, Erick Schampaert, Samer Mansour, Martine Montigny, Mark Eisenberg, 
Claude Lauzon, Jean-Pierre Dery, Michel Nguyen, Philippe L’Allier, Richard Harvey, Caroline Boudreault, Jean Claude Tardif, McGill Health 
University Center, Montreal, Canada
background: Previous studies showed gaps in prescription of evidence-based medical therapy (EBMT) for acute coronary syndromes 
(ACS). We hypothesized that knowledge translation (KT) may increase EBMT’s prescription.
methods:  The AMI-OPTIMA study was a cluster randomized controlled trial of 24 hospitals to one-year KT vs usual care. During one year, 
hospitals randomized to KT completed: 1) revision of the most recent American Heart Association Guidelines of ACS management, 2) focus 
groups to identify and solve local care gaps, and 3)local champion team to promote EBMT. At each hospital, we reviewed and compared 
the discharge prescriptions of 100 consecutive ACS patients before and 100 consecutive patients after the year of KT or usual care.EBMT 
was pre-defined as in-hospital anticoagulation and discharge prescription of dual anti-platelets, beta-blockers, statins, and angiotensin 
pathway modulating agents (for patients with impaired left ventricular systolic function). Refusal, impaired cognitive function, allergy or 
intolerance of patients to any of EBMT were considered valid reasons for withholding EBMT.
Results:  There were 4,449 patients with complete data: 2,187 and 2,262 before and after KT/usual care. EBMT was prescribed for 76% of 
patients before and 89% of patients after KT/usual care (p<0.001). There was no significant difference in the median absolute changes of 
EBMT’s prescription: 14.5% (interquartile range (IQR): 8.5%-17.85) among KT hospitals vs 14.0% (IQR: 0.25%-20.0%) (p:0.65) at hospitals 
randomized to usual therapy. We observed decreases in EBMT prescription at 3 hospitals randomized to usual care vs none of the KT hospital 
(p:0.03). EBMT prescription was highly variable in the hospitals randomized to usual care (changes in EBMT prescription: 34% to -8%).
conclusion:  Although KT was not significantly associated with increased EBMT’s prescription, increased EBMT’s prescription was 
observed in all KT hospitals whereas temporal change of EBMT’s prescription was more variable across hospitals randomized to usual 
care. Our results suggest that KT may be effective in ensuring reliable improvement of EBMT prescription for ACS patients.
